Therapy News and Research

RSS

Scientists discover origin of Barrett's esophagus

Dr Frank McKeon, Senior Group Leader of the Stem Cell and Developmental Biology at A*STAR's Genome Institute of Singapore, and Principal Investigator Dr Wa Xian at A*STAR's Institute of Medical Biology, together with their counterparts from the Harvard Medical School, the Brigham and Women's Hospital in Boston, and the National University of Singapore, have made the striking finding that Barrett's esophagus work, published online in the journal Cell on 24 June 2011, is essential to developing therapeutics for esophageal cancer.

28 Jun 2011

TrialNet presents Diamyd Phase II study results on type 1 diabetes at ADA 2011

The American research consortium Type 1 Diabetes TrialNet presented their results of a Phase II study with the antigen-based diabetes therapy Diamyd yesterday, June 27, at the American Diabetes Association 71st Scientific Sessions (ADA) in San Diego, California, USA, after the closing of the stock market.

28 Jun 2011

Women can benefit from immediate breast reconstruction following mastectomy

For women undergoing mastectomy for breast cancer, immediate breast reconstruction has a low risk of complications—including serious complications related to radiation therapy—and does not cause undue delays in cancer treatment, reports a study in the July issue of Plastic and Reconstructive Surgery, the official medical journal of the American Society of Plastic Surgeons.

28 Jun 2011

Researchers, policy experts to examine issue of declining enrollment in clinical trials

Leading researchers and policy experts from across the country will come together June 27 and June 28 at Mount Sinai School of Medicine in New York to examine the issue of declining enrollment in clinical trials.

28 Jun 2011

Marshall Edwards' Triphendiol pre-clinical study data now available in Anti-Cancer Drugs website

Marshall Edwards, Inc., an oncology company focused on the clinical development of novel therapeutics targeting cancer metabolism, announced today the publication of results from pre-clinical studies of Triphendiol, a prodrug of the Company's lead drug candidate NV-143, that demonstrate its anti-proliferative activity in pancreatic cancer as both a monotherapy and as a chemosensitizer.

28 Jun 2011

Amgen files sBLA for XGEVA with FDA to treat castrate-resistant prostate cancer

Amgen today announced the submission of a supplemental Biologics License Application (sBLA) to the U.S. Food and Drug Administration (FDA) to expand the indication for XGEVA (denosumab) to treat men with castrate-resistant prostate cancer to reduce the risk of developing bone metastases.

28 Jun 2011

Circulation journal publishes Celladon's MYDICAR Phase 2 trial on advanced heart failure

Celladon Corp., a biopharmaceutical company focused on the discovery and development of innovative treatments for cardiovascular diseases, announces that the data from its completed Phase 2 CUPID clinical study of MYDICAR for the treatment of advanced heart failure is being published today online in Circulation, an American Heart Association journal.

28 Jun 2011

On-X LTI announces four clinical trial results of Prosthetic Heart Valve

On-X Life Technologies, Inc. announced today that four clinical trial reports, documenting the On-X Prosthetic Heart Valve's extraordinary performance, will be presented at the upcoming meeting of the Society for Heart Valve Disease in Barcelona, Spain being held June 25-28, 2011.

28 Jun 2011

Nile completes dosing in Part B of cenderitide Phase I study for ADHF

Nile Therapeutics, Inc., a biopharmaceutical company that develops novel therapeutics for heart failure patients, today announced that it has completed dosing the first patient in Part B of the ongoing Phase I study.

27 Jun 2011

West End Orthopaedic Clinic announces name change to OrthoVirginia

West End Orthopaedic Clinic has announced that they are changing the name of their practice to OrthoVirginia. Coinciding with the name change will be the opening of a new facility completely dedicated to orthopedic specialty care and sports medicine, at the Boulders near Chippenham Hospital.

27 Jun 2011

Positive top line data from Mimetogen MIM-D3 Phase II clinical trial for dry eye disease

Mimetogen Pharmaceuticals Inc. today announced positive top line data from the Phase II clinical trial of MIM-D3 for dry eye disease. The trial demonstrated statistically significant improvements in signs and symptoms with its low (1%) and high (5%) doses of MIM-D3, together with excellent safety and tolerability profiles.

27 Jun 2011

NovaSom completes $35M equity financing led by Safeguard Scientifics

NovaSom, Inc., the market leader in technology-driven, payer-aligned cost-saving solutions for Obstructive Sleep Apnea (OSA) management, today announced it has closed $35 million in equity financing.

27 Jun 2011

Teva concludes Site Initiation Visit for Israeli clinical center in CEL-SCI's Multikine Phase III clinical trial

CEL-SCI Corporation announced today that its partner Teva Pharmaceuticals, a leading global pharmaceutical company, has concluded the Site Initiation Visit for the first Israeli clinical center in CEL-SCI's Phase III clinical trial for Multikine, the Company's flagship cancer immunotherapy.

27 Jun 2011

EnVivo initiates EVP-0962 GSM Phase 1 clinical trial for Alzheimer’s disease

EnVivo Pharmaceuticals, a company dedicated to developing a broad range of novel central nervous system (CNS) therapies, announced today that it recently initiated a Phase 1 clinical trial of EVP-0962, its potent and selective gamma secretase modulator (GSM), in healthy volunteers.

27 Jun 2011

FDA responds to EpiCept Ceplene SPA

EpiCept Corporation today announced that it has received initial written responses from the U.S. Food and Drug Administration regarding the Company's application for a Special Protocol Assessment (SPA) of the Ceplene (histamine dihydrochloride) Phase III protocol.

27 Jun 2011

Chaos in biochemical alterations of cancer cells

Using the latest gene sequencing tools to examine so-called epigenetic influences on the DNA makeup of colon cancer, a Johns Hopkins team says its results suggest cancer treatment might eventually be more tolerable and successful if therapies could focus on helping cancer cells get back to normal in addition to strategies for killing them.

27 Jun 2011

Prostate cancer therapy may benefit patients with oestrogen-negative breast cancer

CANCER RESEARCH UK Cancer Research UK scientists have discovered why a sub group of oestrogen-receptor-negative breast cancer patients could benefit from prostate cancer treatments which target the cell's androgen receptor - a key driver of prostate cancer, according to research published in The EMBO Journal today.

27 Jun 2011

Yissum, BioLineRx sign license deal to develop and commercialize BL-7040 for IBD

BioLineRx, a biopharmaceutical drug development company, and Yissum Research Development Company Ltd., the Technology Transfer Company of the Hebrew University of Jerusalem, announced today that they have signed a worldwide, exclusive license agreement for BioLineRx to develop and commercialize BL-7040, an orally available Phase II ready molecule for treating Inflammatory Bowel Disease (IBD) and other inflammatory diseases.

27 Jun 2011

Enrollment complete in ERYTECH Pharma's Graspa Phase I clinical trial for pancreatic cancer

ERYTECH Pharma has just completed the enrollment of patients in a Phase I clinical trial with its flagship product for pancreatic cancer, Graspa®. This product contains the enzyme L-asparaginase encapsulated in red blood cells, using technology owned by ERYTECH Pharma.

27 Jun 2011

Study aims to find out whether blood screening can diagnose early breast cancer

A study spearheaded by the University of Leicester aims to find out whether a blood test can detect cancer, earlier than current methods, in women with a strong family history of breast cancer.

27 Jun 2011

Therapy News and Research

Scientists discover origin of Barrett's esophagus

TrialNet presents Diamyd Phase II study results on type 1 diabetes at ADA 2011

Women can benefit from immediate breast reconstruction following mastectomy

Researchers, policy experts to examine issue of declining enrollment in clinical trials

Marshall Edwards' Triphendiol pre-clinical study data now available in Anti-Cancer Drugs website

Amgen files sBLA for XGEVA with FDA to treat castrate-resistant prostate cancer

Circulation journal publishes Celladon's MYDICAR Phase 2 trial on advanced heart failure

On-X LTI announces four clinical trial results of Prosthetic Heart Valve

Nile completes dosing in Part B of cenderitide Phase I study for ADHF

West End Orthopaedic Clinic announces name change to OrthoVirginia

Positive top line data from Mimetogen MIM-D3 Phase II clinical trial for dry eye disease

NovaSom completes $35M equity financing led by Safeguard Scientifics

Teva concludes Site Initiation Visit for Israeli clinical center in CEL-SCI's Multikine Phase III clinical trial

EnVivo initiates EVP-0962 GSM Phase 1 clinical trial for Alzheimer’s disease

FDA responds to EpiCept Ceplene SPA

Chaos in biochemical alterations of cancer cells

Prostate cancer therapy may benefit patients with oestrogen-negative breast cancer

Yissum, BioLineRx sign license deal to develop and commercialize BL-7040 for IBD

Enrollment complete in ERYTECH Pharma's Graspa Phase I clinical trial for pancreatic cancer

Study aims to find out whether blood screening can diagnose early breast cancer

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo

Advancing Intracellular Delivery with LumiPore®

Latest News